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chronic HF is nutrition impairment, which predicts
early death in patients of all ages with HF.3
Independently living patients with HF require similar
total daily calories to those of age-matched healthy con-
trol individuals, despite decreases in both total body and
lean body mass in the HF group.4 However, some investi-
gators report an increase in resting energy expenditure
among those with severe HF due to elevated resting
peripheral oxygen consumption and increased cardiac
and ventilatory work.4-7 Drug therapy in patients with HF
creates multiple nutrition issues that are problematic. As
numerous medications are associated with a variety
of adverse effects, it is typically reasonable to treat
the underlying cause in a symptomatic patient and
discontinue the offending agent. However, many of the
medications used for HF either alleviate symptoms or
strongly affect disease progression and HF-related
mortality, and it would therefore not be desirable to dis-
continue the causative medication.
Remarkably, apart from the fact that a high-sodium
diet is detrimental, little is known about specific
consequences of nutrient deficiencies or long-term
outcomes of dietary supplementation. This review
summarizes drug- and disease-specific nutrition issues,
evidence for available treatment modalities, and strate-
gies for the clinician treating HF patients with
nutrition impairments.
General Issues
Heart failure (HF) has emerged as a disease with sig-
nificant public health implications. There are more
than 5 million individuals with HF in the United
States, and more than 600,000 new cases are diagnosed
annually.1 These patients generate 12–15 million office
visits for HF each year; more than 280,000 patients die
of HF each year.2 Despite improved availability of
sophisticated diagnostic techniques and use of modern
therapies, the risk of death within 5 years of diagnosis
is > 50%.2 Among the risk factors for mortality in
Nutrition impairment commonly occurs in patients with heart fail-
ure and affects disease progression. Vitamin and mineral deficien-
cies are associated with early mortality, particularly in patients
classified as cachectic. Guideline-based therapies approved for
heart failure, such as loop diuretics, angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers, aldosterone
antagonists, and β-adrenergic blockers, can lead to electrolyte
abnormalities and predispose to some vitamin and micronutrient
deficits. Clinical trial evidence in support of supplementary vita-
min and mineral therapies for heart failure patients is limited with
the exception of documented calcium and possibly vitamin D, thi-
amine, and coenzyme Q10 deficiencies. This area is gaining signif-
icant attention, and research is ongoing. The clinician can help
minimize morbidity from nutrition impairment through appropri-
ate monitoring and correction of baseline and medication-induced
electrolyte imbalances, in addition to vitamin and mineral supple-
mentation when appropriate. (Nutr Clin Pract. 2009;24:60-75)
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Malnutrition and HF
Excessive salt and fluid intakes are important factors that
worsen HF symptoms, leading to acute HF and hospitaliza-
tions. Deficiencies of vitamins and micronutrients also play
an important role in the pathophysiology of this syndrome.8
The frequency of malnutrition varies according to HF sever-
ity, ranging from 22% in New York Heart Association
(NYHA) functional class II to 63% in class III.9 The impact
of malnutrition was examined in a follow-up study of
approximately 230 older adults admitted to an emergency
department for various medical problems including HF.
Mortality rates for the 41 malnourished patients was 44%,
compared with 18% in 164 nonmalnourished patients (P <
.001). Of note, the majority of malnourished patients con-
comitantly had HF.10 Other investigators studied the impact
of cachexia on mortality in 171 HF patients. Cachectic par-
ticipants exhibited 29% mortality at 6 months, 39% at 12
months, and 50% at 18 months. The cachectic state pre-
dicted 18-month mortality independent of age, NYHA class,
left ventricular ejection fraction (EF), and peak oxygen con-
sumption.3
The pathophysiology of HF exerts direct effects on
metabolism and intestinal function. These include intes-
tinal ischemia and inflammation, hypercatabolism, nutri-
tion malabsorption, and anorexia.11 Increased sympathetic
nervous system (SNS) activity in HF patients causes
vasoconstriction of splanchnic circulation12,13 and creates
hypoxia and ischemia of the gut mucosa, which leads to
impaired epithelial function and increased mucosal perme-
ability.14 Intestinal ischemia is quantified by elevated intes-
tinal pCO2 and reduced intestinal pH, and may contribute
to the inflammatory nature of HF pathophysiology.15 Reduced
mucosal perfusion diminishes the mucus barrier that isolates
epithelial cells from intestinal flora.16 Compromised by dimin-
ished protective mucus, reduced host immune function, and
increased permeability, the ischemic mucosa is a prime target
for bacterial translocation into the splanchnic lymphatic sys-
tem.13 Bacterial translocation increases exposure to
lipopolysaccharide endotoxin, which in turn stimulates
macrophage release of inflammatory cytokines (eg, tumor
necrosis factor [TNF]-α) and further SNS activation.13,16,17
Intestinal mucosal ischemia and inflammation may further
contribute to the development of anorexia, malabsorption,
and cardiac cachexia in HF patients.18,19
Hypercatabolism stems from activation of catabolic
factors such as norepinephrine, epinephrine, and inflam-
matory cytokines, which also worsen overall disease pro-
gression in HF.11 Moreover, reduced concentrations of
the anabolic hormone dehydroepiandrosterone sulfate in
HF lend support to the link between malnutrition in car-
diovascular disease and alterations in anabolic-catabolic
balance.20 The failing heart releases cytokines such as
TNF-α, which exert exocrine and endocrine effects and
cause significantly altered body composition including
reduced lean body mass, bone mass, and fat content.21
Altered gut absorption can also affect nutrition defi-
ciencies in patients with HF. Reduced gut circulation and
disturbed microcirculation in HF contribute to local
edema of the gastrointestinal (GI) tract. Gut edema
causes GI malabsorption and impairs adequate nutrition.
Fat absorption is particularly affected, leading to potential
deficiencies in fat-soluble vitamins.22,23 Protein loss also
occurs, contributing to development of cardiac
cachexia.24
Anorexia may develop in HF patients secondary to
nausea from gut edema or as an adverse effect from
medications, early satiety from hepatic edema, or depressive
symptoms that cause a loss of appetite.
Cardiac Cachexia
Although there is no agreement as to how cachexia is
defined, the hallmark clinical characteristic of cachexia is
the process of losing weight, which can be defined as
nonedematous weight loss of >6% of the previous normal
weight over a period of >6 months.25 The frequent pres-
ence of edema in HF patients complicates assessment of
weight loss. Lean body assessments should ideally be
performed by methods that account for total body water
(bioimpedance) or non–weight-based assessments (anthro-
pometric measurements).26
The prognosis of HF worsens considerably once
cardiac cachexia has been diagnosed, regardless of HF
severity. Mortality rates are estimated at 50% for HF
patients and cachexia compared to 17% for noncachectic
patients of the same population.3 It is important to
distinguish cachexia from malnutrition and anorexia, as
the latter are reversible once nutrition is supplied. In
addition, muscle mass is mostly spared in malnutrition
and anorexia at the expense of fat mass. Patients exhibit-
ing cachexia lose muscle mass in addition to total fat and
bone mineral density.25,27 Some of the underlying patho-
physiology concerning malnutrition and cachexia are
similar, including neurohormonal activation and involve-
ment of inflammatory cytokines as mentioned earlier.
Acute illness in HF patients portends hypermetabolic
changes and, combined with chronic cardiac cachexia,
makes nutrition requirements difficult to assess (Table 1).
Obesity Paradox
The health hazards of obesity and elevated body mass
index (BMI) are well accepted in the general popula-
tion.28-32 Recommendations for weight loss and target
BMI are incorporated into contemporary guidelines for
the management of hypertension, hyperlipidemia, and
acute coronary syndromes.33-36 Among patients with HF,
however, increasing BMI is paradoxically associated with
improved cardiovascular outcomes and survival.37-39
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The most compelling evidence for this association
comes from an investigation of the impact of BMI on out-
comes in 7767 HF patients enrolled in the Digitalis
Investigation Group trial.40 Over a mean follow-up of 37
months, patients with BMIs in the obese (>30 kg/m2) or
overweight (25–29.9 kg/m2) ranges experienced mortality
rates of 28.4% and 32.4%, respectively, whereas patients
with BMIs in the underweight (<18.5 kg/m2) or normal
(18.5–24.9 kg/m2) range experienced mortality rates of
37.8% and 45.0%, respectively. After multivariate analysis
that included left ventricular EF, HF etiology, gender, and
duration of HF symptoms, the mortality hazard ratios
(HRs) for obese BMI (0.80; 95% confidence interval
[CI], 0.72–0.92) and overweight BMI (0.88; 95% CI,
0.80–0.96) were statistically lower than was the reference
normal BMI (predefined as 1.00) or underweight BMI
(1.21; 95% CI, 0.95–1.53). Of note, these mortality
effects were not associated with a measurable difference
in hospitalization rates.
The physiologic mechanism underlying the obesity
paradox is not well understood. Proposed mechanisms
include increased health concerns for those with ele-
vated BMI, resulting in earlier detection and treatment
of HF in these patients, thus accounting for reduced
mortality.41,42 Others hypothesized that malnourish-
ment and cardiac cachexia are more prevalent in low
BMI groups, driving the mortality findings.18,40 However,
the obesity paradox retains significance after exclusion
of patients with cardiac cachexia.38
Pharmacotherapy for the Prevention and
Treatment of Cardiac Cachexia
Evidence supports pharmacotherapeutic interventions
for preventing and treating cardiac cachexia. In the
SOLVD trial, participants treated with enalapril had
less weight loss of ≥6% (HR, 0.81; 95% CI, 0.70–0.94;
P = .0054).18 Similar results in anthropometric indices
were observed in 8 patients receiving a combination of
enalapril, digoxin, and furosemide therapy.43 Investigators
found significant increases in midupper arm circumference
and plasma albumin in individuals receiving the com-
bination compared to healthy volunteers. Beta-blockers
have also shown beneficial effects on nutrition status.
Anker et al demonstrated that both carvedilol and biso-
prolol increased the percentage of patients without
significant weight loss in the COPERNICUS and CIBIS-II
trials, respectively.44,45 Similarly, Hryniewicz et al pro-
spectively measured changes in nutrition status in 27
cachectic and noncachectic HF patients after 6 months
of treatment with extended release metoprolol or
carvedilol.46 Cachectic patients demonstrated significant
nonedematous weight gain (5.2 ± 9.6 vs 0.8 ± 5.0 kg,
P = .027) and plasma leptin levels (3.7 ± 3.9 vs 1.2 ± 4.3
ng/mL, P = .030) when compared with noncachectic
patients. Although precise mechanisms that these
medications have on preventing or improving cachexia
have not been fully identified, the actions of angiotensine-
converting enzyme inhibitors (ACEIs) and beta-blockers
on attenuating overregulated neurohormonal systems by
decreasing circulating catecholamines and harmful
inflammatory cytokines such as TNF-α and interleukin-6
appear to play a prominent role. Multiple effects of the SNS
on resting metabolic state in HF have been documented.47
As both β-blockers and renin-angiotensin-aldosterone sys-
tem (RAAS) inhibition with ACEI or angiotensin receptor
blockers (ARBs) improve mortality and morbidity in this dis-
ease state, maximizing the use of these agents is the first
step in preventing cardiac cachexia.
Many pharmacotherapeutic options are available to
treat cachexia, although few have been optimally evalu-
ated in clinical trials with HF patients. Malkin et al con-
ducted a double-blind, randomized controlled trial of
testosterone replacement in 76 men with HF over 12
months.48 At the end of the study, participants receiving
testosterone demonstrated increases in incremental shut-
tle walk test (25 ± 15 m in the treatment group, P = .006,
ANOVA vs placebo). In addition, Pugh et al observed acute
changes in cardiac output with the use of testosterone at
Table 1. Physiologic Contributors to
Malnutrition and Cachexia in Heart Failure
Intestinal ischemia Decreased splanchnic circulation from
increased SNS activity: (1) impaired 
epithelial function and increased 
mucosal permeability; (2) exposure to 
endotoxin and inflammatory cytokine 
release
Hypercatabolism Increased levels of stress hormones and 
neurohormones: (1) epinephrine; (2) 
norepinephrine; (3) cortisol
Decreased levels of anabolic hormones: 
(1) dehydroepiandrosterone sulfate; (2) 
insulin-like growth factor-1
Increased circulating levels of cytokines
Malabsorption Reduced gut circulation
Gut edema: (1) decreased fat absorption; 
(2) protein loss




SNS, sympathetic nervous system.
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180 minutes (10.3% ± 4.6%, P = .035; 95% CI, 0.8–19.8)
in a randomized, placebo-controlled, crossover trial in 12
men with HF.49 The use of growth hormone was examined
by Tritos and Danias in a meta-analysis of 14 trials total-
ing 212 patients with left ventricular systolic dysfunction.
Findings indicated that growth hormone improved exer-
cise duration (1.9 minutes; 95% CI, 1.1-2.7), maximum
oxygen consumption (2.1 mL/ kg/min; 95% CI, 1.2-3.0),
NYHA functional class (–0.9; 95% CI, –1.5 to –0.3), and
EF (4.3%; 95% CI, 2.2-6.4) relative to placebo.50
Megestrol and medroxyprogesterone are oral deriva-
tives of progesterone used to stimulate appetite in various
conditions.51 Both successfully increase weight in
patients with cancer.52,53 The appetite-enhancing mecha-
nism of megestrol, the more commonly prescribed of the
2 agents, is still unknown but thought to be owing to the
production of neuropeptide Y, a central appetite stimu-
lant.54 Medroxyprogesterone reduces humoral factors
involved in the cachectic response, such as serotonin,
interleukin-6, and TNF-α.55 Data are lacking for use of
megestrol or medroxyprogesterone for cachexia in HF
patients. The dose of megestrol is 800 mg/d for appetite
stimulation, not to be confused with dosing for other
disease states. Side effects of megestrol include diarrhea,
thrombotic events, confusion/hallucinations, hyperglycemia,
headache, Cushing syndrome, and antitestosterone
effects in men.56 Because of its side effect profile, the use
of megestrol should be reserved for extreme cases of
cachexia in HF patients.
Growth hormone has been another target for improv-
ing appetite in cachexia. Ghrelin, a stimulator of growth
hormone release from the pituitary, is secreted from the
stomach and transmits the hunger signal to the peripheral
and central nervous system. In HF, ghrelin has been
shown to increase muscle strength and lean body mass as
well as improve left ventricular EF.57 Although initial
studies showed promise, controlled studies of ghrelin in
HF have been negative to date, and presently it is not
available in the United States.58,59
Cannabinoids, the active chemical in marijuana, are
a group of molecules that positively affect appetite and
weight in cancer patients.51 The mechanism of these
agents remains unknown but is thought to be mediated
by endorphin receptors or by inhibiting prostaglandin
synthesis. These agents are controlled substances due to
their abuse potential and should be used with caution for
cachexia in HF.
Other agents that have been thought to improve
cachexia include cyproheptadine, anabolic steroids, and
corticosteroids.56 None of the drugs discussed have been
shown to effectively improve the disease process in HF
cachexia. Therefore, the main therapeutic strategy for
cachexia in HF is to treat the underlying condition
through optimization of currently approved therapies.
Nutrition Effects of Drugs
Commonly Used in HF
Loop Diuretics
Potassium and magnesium deficiency. Diuretic use is asso-
ciated with electrolyte depletion, the most concerning of
which is potassium, an essential cation for maintaining
normal heart rhythm and function. Loop diuretics reduce
potassium reabsorption at the site of action and enhance
potassium secretion in the distal tubules of the nephron.60
Secondary increases in aldosterone can also contribute
to hypokalemia after administration of loop diuretics.60
A pharmacodynamic evaluation of the loop diuretic
bumetanide showed a 3-fold increase in urinary total
potassium excretion compared with excretion associated
with a placebo.61 This was similar to that observed with
equipotent doses of furosemide and greater than the
potassium excretion with the thiazide-type diuretic
hydrochlorothiazide.61 Another study also demonstrated
significant increases in urinary magnesium, calcium, and
phosphate excretion with loop diuretics.62 The clinical
implications of electrolyte depletion include ventricular
proarrhythmia and sudden cardiac death, which have
been independently associated with increases in all-cause
mortality in an HF population.63-65
Loop diuretics also contribute to the development of
hypomagnesemia and hypocalcemia as magnesium and
calcium reabsorption in the thick ascending limb is
dependent on sodium and chloride concentrations. In a
study of 68 patients admitted for HF, hypomagnesemia
existed in 38% of the cohort on admission, and excessive
magnesium loss was observed in 72% of patients.66 Like
hypokalemia, hypomagnesemia has also been associated
with adverse cardiac events. In a trial of 45 HF patients
who received 4 weeks of diuretic therapy, magnesium
concentrations were not significantly different overall
but were lower in the patients who experienced frequent
premature ventricular contractions.67
Management of hypokalemia and hypomagnesemia
as a result of diuretic therapy is challenging in an aggres-
sively managed HF patient. This challenge is further
compounded by the fact that diuretic use is dynamic and
frequently titrated according to patient symptoms.
Furthermore, overly aggressive diuretic use can induce a
prerenal acute renal failure as a result of intravascular
volume depletion, potentially placing the patient at risk
for hyperkalemia from potassium supplementation or
other medications that can elevate serum potassium
levels. Prevention of adverse effects from potassium and
magnesium is therefore dependent on proper attention to
diuretic requirement. An additional consideration is that
homoeostasis of magnesium and potassium is closely
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related, possibly due to the influence of magnesium on
the Na/K/ATPase pump.68 Therefore, hypomagnesemia
must be corrected before potassium replacement.
Although many clinicians elect to supplement potas-
sium as hypokalemia is identified, proper focus should
also be placed on prevention. Clinicians should consider
proactive potassium supplementation when initiating
or increasing doses of loop diuretics. Likewise, dietary
supplementation may be reasonable with foods high in
potassium, such as bananas, tomato juice, and potatoes,
among other foods. Dietary approaches to prevent
hypokalemia were validated in cardiac surgery patients
receiving < 160 mg/d of furosemide and may be reason-
able in a patient with mild HF.69 However, many patients
with severe HF receiving high-dose or combination
diuretic therapy may have deficiencies that exceed even
conscious efforts to increase dietary potassium.
Concomitant use of medications that will both modify the
disease progress of HF and increase serum potassium,
such as ACEIs and ARBs, may offset the hypokalemic
effect of loop diuretics,70-73 in a dose-dependent fashion.74
Likewise, an aldosterone antagonist such as spironolac-
tone or eplerenone may also increase serum potassium
levels in an additive or even synergistic manner with other
RAAS inhibitors.75 The ACEIs or ARBs titrated to target
doses are recommended for all patients with systolic HF
due to their beneficial effects on ventricular remodeling
and mortality.2 Aldosterone antagonists are approved
for patients with left ventricular systolic dysfunction after
myocardial infarction or those with NYHA functional
classes III to IV.2 Some clinicians use spironolactone
or eplerenone in patients with mild HF with persistent
hypokalemia or for a patient intolerant of oral potassium
supplementation. Because spironolactone has been asso-
ciated with increased death from hyperkalemia in HF,76 it
is prudent to initiate therapy with lower doses such as
12.5 mg daily and monitor serum potassium during the
initial phase of therapy.
Acutely ill HF patients undergoing aggressive diuresis
at a rate of several liters per day will require daily moni-
toring of serum potassium and magnesium to prevent
severe deficiency. Likewise, when diuretic therapy is
changed in the outpatient setting, patients will have vari-
able potassium and magnesium requirements. Clinicians
should be cognizant of these medication changes and
learn to anticipate supplement requirements. For exam-
ple, discontinuation or modification of diuretic therapy
should prompt discontinuation or reduction in potassium
and magnesium supplementation. It is also worth noting
that use of a thiazide diuretic in combination with a loop
diuretic (a combination used in patients not responsive to
loop diuretics alone) will result in synergistic diuresis as
well as increased potassium and magnesium depletion.77
Closer attention to potassium and magnesium supple-
mentation is required with combination diuretic agents.
Thiamine deficiency. Thiamine is a water-soluble B vitamin
(vitamin B1) that is an important coenzyme in carbohy-
drate energy metabolism. Thiamine is not synthesized by
humans and requires routine ingestion to maintain
adequate stores. Thiamine comes from a variety of food
sources, such as whole grain cereals, lentils, nuts, and
yeast.78 Once ingested, a portion is retained in the skele-
tal muscle, the heart, and other highly metabolic tissues
while excess is excreted in the urine. Thiamine deficiency
can occur rapidly, within 2–3 weeks of diminished intake
or increased excretion.79 Wet beriberi is a syndrome of
thiamine deficiency characterized by sodium retention,
peripheral vasodilatation, and biventricular HF. Numerous
studies have evaluated thiamine deficiency in patients
with HF, and with the exception of alcoholic cardiomy-
opathy or with chronic diuretic use, most found a fairly
low occurrence that increases with advanced age.80
There are several potential factors associated with
thiamine deficiency in HF patients, including alcohol
ingestion, loop diuretic use, malnutrition, advanced age,
and HF severity. Alcohol interferes with thiamine absorp-
tion, and the chronic alcoholic may present with severe
nutrition deficiency and profound but reversible HF. The
prognosis in these cases depends on the duration of
chronic alcohol intake, underlying myocardial structural
abnormalities, and other contributing HF etiologies.
Chronic diuretic therapy may precipitate thiamine
deficiency. By increasing urinary flow, diuretics may pre-
vent reabsorption of thiamine and increase its urinary
excretion.81 One study in 25 patients with HF found a
98% prevalence of thiamine deficiency associated with
furosemide use at doses of 80 mg/d or greater.82 The same
study showed that 57% of patients taking lower diuretic
doses developed thiamine deficiency as well. Suter observed
a similar association with diuretic use and thiamine status
in 149 older adult patients hospitalized with a cardiac
condition.83 Multiple regression modeling revealed that
the only independent predictor of change in thiamine
concentration was diuretic use.83 Although thiamine
deficiency occurs quickly and profoundly with high diuretic
doses, the practitioner must also consider this potential
adverse drug event in patients given smaller doses of diuret-
ics on a chronic basis.84
Given the potential adverse effects of diuretic-
induced thiamine deficiency, several investigations have
explored thiamine replacement in patients with HF.
Seligmann et al reported pilot findings with 6 patients
identified with loop diuretic–induced thiamine deficiency
who received 100 mg of thiamine intravenously for 7
days.85 Thiamine deficiency, as measured by thiamine
pyrophosphate effect, improved in all 6 patients, and
increases in EF were identified in 4 of the 5 patients who
underwent echocardiography. A follow-up double-blind
study was conducted by Shimon et al, in which 30 hospi-
talized patients with diuretic-induced thiamine deficiency
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were randomized to either intravenous (IV) thiamine at 200
mg/d or placebo for 1 week.86 After discharge, all 30 par-
ticipants received oral thiamine at 200 mg/d for 6 weeks.
After 1 week, EF was mildly improved in the participants
randomized to receive thiamine (0.28 ± 0.11 to 0.32 ±
0.09; P < .05) and further improved in all 27 participants
who completed the remaining 6-week study medication
course (0.27 ± 0.10 to 0.33 ± 0.11; P < .01). No signifi-
cant changes in EF were observed in participants receiv-
ing placebo. Mild, although statistically significant,
changes in diuresis rates and sodium excretion were also
observed in patients randomized to thiamine replacement
(1731 ± 800 mL/d to 2389 ± 752 mL/d [P < .02] and
84 ± 52 mEq/d to 116 ± 83 mEq/d, respectively). Finally,
Smithline reported the results of a trial in which 50
patients with acute decompensated HF on chronic diuretic
therapy were randomized to receive 100 mg of IV thiamine
within 30 minutes of arrival to the emergency depart-
ment.87 No changes were observed in the percentage of
patients hospitalized, length of stay, or 4-hour dyspnea
score.
Given the lack of robust randomized controlled data,
it is difficult to make definitive recommendations on the
use of thiamine supplementation in HF patients. Diuretic
therapy has been widely associated with thiamine
deficiency, although the clinical utility of normalizing
thiamine in HF has not been optimally evaluated. It
would be reasonable, however, given the apparent lack of
harm with replacement, to periodically test for thiamine
deficiency in patients on high-dose, chronic loop diuretic
therapy and administer replacement (100-200 mg/d) if
deficiency is identified. Further clinical studies evaluating
the effects of thiamine deficiency on disease progression
in HF and trials of thiamine replacement are warranted to
solidify replacement recommendations.
Drugs Modifying the RAAS
Inhibitors of the RAAS have the potential to cause hyper-
kalemia by interfering with the production and secretion
of aldosterone (Table 2). Hyperkalemia was observed at
statistically higher rates with RAAS inhibitors than with
placebo during clinical trials in patients with HF.88-92 The
RAAS inhibitor-induced hyperkalemia may also be dose
related. In the ATLAS trial, a nonsignificant increase in
incidence of hyperkalemia was observed with high-dose
lisinopril compared with low-dose lisinopril, but there was
no resulting difference in discontinuation rates of study
medication.74 Target ACEI doses used in clinical trials
have demonstrated a decrease for morbidity; therefore,
dose titration is recommended in all patients if toler-
ated.74 In addition to effects on potassium, ACEI and/or
ARB therapy has been shown to increase urinary excre-
tion of zinc,93,94 which is also the suggestive mechanism
for ACEI/ARB-induced dysgeusia.95
The ARBs are among the newest RAAS inhibitors in
the armamentarium for the treatment of HF. It was orig-
inally theorized that ARBs caused potassium retention to
a lesser extent than did ACEIs; however, this was not
observed in patients with normal glomerular filtration
rates in the double-blind, randomized, crossover VAL-K
study.96 The rates of ARB-induced severe hyperkalemia
incidence was 2%–5.5% in clinical trials, compared to
1.7%–6.4% for ACEIs.92,97,98
Aldosterone antagonists, such as spironolactone and
eplerenone, also demonstrate hyperkalemia, which
occurs more commonly at doses of 50 mg daily and
higher.90,91 Patients with elevated baseline serum creati-
nine or potassium should begin therapy with low doses of
12.5 mg daily for spironolactone and 25 mg daily for
eplerenone and receive frequent laboratory monitoring.
Combinations of RAAS inhibitors are often used for
improved outcomes in the treatment of HF. A post hoc
evaluation of hyperkalemia reported in the CHARM trials
showed that age ≥ 75 years, male gender, baseline serum
creatinine ≥ 2.0 mg/dL or potassium ≥ 5.0 mEq/L,
diabetes, and combined RAAS blockade (with an ACEI or
spironolactone) increased the incidence of hyperkalemia
with candesartan.99 A meta-analysis that included 4 trials
of patients receiving combination therapy with an ACEI
and ARB found the incidence of severe hyperkalemia
(≥5.5 mEq/L) to be 3.5% compared with 0.7% in the
placebo group (95% CI, 2.39-9.94).100 The American
Heart Association and the American College of Cardiology
(AHA/ACC) consensus guidelines for the treatment of
HF recommend that the combination of ACEI plus ARB be
considered only if the patient remains symptomatic on opti-
mal medical therapy.2 These guidelines also caution against
use of triple RAAS inhibition due to risk of hyperkalemia.
The risks of hyperkalemia should be carefully consid-
ered in comparison to the known benefits of ACEIs, ARBs,
and aldosterone antagonists on cardiac mortality before
these agents are discontinued. The American Heart
Association/American College of Cardiology (AHA/ACC)
recommend against withdrawal of ACEIs unless serum
creatinine increases by > 30% of baseline or unless serum
potassium rises above 5.5 mEq/L. The AHA scientific
statement specifically addressing renal considerations with
ACEI therapy recommends reducing potassium supple-
ments, decreasing aldosterone antagonist doses, and
increasing diuretic doses as strategies to help with potas-
sium homeostasis during ACEI initiation.101
Beta-Blockers
Beta-adrenergic blockers may precipitate hyperkalemia
by causing redistribution of potassium through the β2
adrenergic receptor, rather than impairing renal excretion.96
Stimulated by the α-adrenergic action of epinephrine,
potassium is released from the intracellular space into the
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serum.102 Subsequently, the beta-adrenergic effects of
epinephrine are thought to restore balance. Therefore,
serum potassium is expected to rise with increasing β2
adrenergic blockade.102 Although the clinical importance
of this is yet to be determined, increased percentage of
beta-blocker use might have contributed to the high rates
of hyperkalemia (5.5%) observed in the eplerenone posta-
cute myocardial infarction HF efficacy and survival study
as compared to earlier spironolactone studies involving a
lower percentage of patients on beta-blockers.91,103 As pre-
viously discussed, hyperkalemia with aldosterone antago-
nists appears to be dose related. However, a retrospective
evaluation of 59 patients with HF receiving carvedilol,
spironolactone, furosemide, and enalapril or candesartan
observed hyperkalemia (≥5.5 mEq/L) in 11.9% of patients
regardless of spironolactone dose.104
Vitamins and Over-the-Counter
Medications in HF
Vitamin Deficiencies and Supplementation
HF patients are often deficient in many vitamins and
micronutrients crucial to the maintenance of calcium
homeostasis, control of oxidative stress, and adequate pro-
tein metabolism.105 Excess reactive oxygen species and
markers of increased oxidative stress have been correlated
with the failing myocardium and may contribute to beta-
receptor hyporesponsiveness.22 Moreover, patients with
HF may possess different nutrition needs compared to
individuals with a normal myocardium, leading to higher
requirements for certain vitamins and micronutrients
(Table 3). As such, the following section includes vitamins
Table 2. Recommendations for the Treatment and Prevention of Detrimental
Drug-Induced Nutrition Effects in Patients with Heart Failure
Effect Drug-Induced Cause Recommendation
Hypokalemia Loop diuretics Monitor serum potassium level every 3–6 months if stable; monitor every 2–4
weeks until stable if initiation or change in dosage of any of the following: (1) 
ACEI/ARB; (2) loop or thiazide diuretic; (3) potassium supplement; (4)
aldosterone antagonist
Maximize ACEI/ARB therapy
Consider the addition of an aldosterone inhibitor
Consider dietary or pharmacologic potassium supplementation
Anticipate use of diuretic therapy
Hyperkalemia Potassium supplements; Monitor serum potassium level every 3–6 months if stable; monitor every 2–4 
ACEIs; aldosterone weeks until stable if initiation or change in dosage of any of the following: (1) 
antagonists; ACEI/ARB; (2) loop or thiazide diuretic; (3) potassium supplement
beta-blockers; Monitor serum potassium within a week of initiation of aldosterone antagonist,
aggressive diuretic then every 2–4 weeks until stable or following dose adjustment; monitor every 
use 3–6 months if stable
Monitor serum potassium closely when combination inhibitors of RAAS are used; 
guidelines recommend clinical trial protocols of 48 hours after initiation, then at 
1, 4, and 5 weeks
Adjust use of potassium supplementation with diuretic use or when combination 
inhibitors of RAAS are used
Hypomagnesemia Loop diuretics Monitor serum magnesium level weekly after initiation or change in diuretic dose
and every 3–6 months afterwards if stable
Consider dietary and pharmacologic magnesium supplementation
Anticipate use of diuretic therapy
Thiamine Loop diuretics Consider supplementation with 100–200 mg/d if receiving chronic, high-dose, 
deficiency loop diuretic therapy and deficient in TPPE
Calcium Loop diuretics Aggressively supplement if hypocalcemia is the suspected cause of heart failure
deficiency Monitor serum calcium levels and supplement if receiving chronic loop diuretic 
therapy
Zinc deficiency ACEIs or ARBs; Routine monitoring and supplementation not recommended
thiazide diuretics Consider supplementation if dysgeusia symptoms present in patient receiving ACEI 
or ARB therapy
ACEI, angiotensine-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAAS, renin-angiotensin-aldosterone system;
TPPE, thiamine pyrophosphate effect.
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and micronutrients that either are deficient in HF and/or
are deemed especially important in this setting.
Calcium and vitamin D. Calcium and vitamin D deficien-
cies have been identified in HF patients. Vitamin D is a
major factor in calcium homeostasis, and long-term
hypocalcemia or vitamin D deficiency can lead to clinical
features such as osteoporosis and secondary hyper-
parathyroidism. There is also increasing evidence that
vitamin D deficiency may play a role in the pathogenesis
Table 3. Recommendations for Supplementary Vitamins, Over-the-Counter Medications, and
Complementary and Alternative Medications (CAMs) in Patients with Heart Failure (HF)
Biological Action
Vitamin/Medication Relevant to HF Clinical Effect Recommendation
Calcium Increased myocardial Improvement of systolic Rule out hypocalcemia as reversible cause of 
contractility; reduced dysfunction where cardiomyopathy; monitor and supplement if on chronic 
incidence of hypocalcemia is loop diuretic therapy
osteoporosis suspected cause
Vitamin D Regulation of bone Reduction in Consider increased environmental exposure or 
metabolism and neurohormones, blood supplementation with 50 μg/d of vitamin D or 
myocardial pressure; decreased calcitriol if severe cardiorenal syndrome present
contractility inflammation
B vitamins Red blood cell Decreased homocysteine; Routine supplementation or monitoring not 
production; no proven effect on recommended, except in cases of alcoholic 
regulation of cardiovascular events cardiomyopathy or macrocytic anemia
homocysteine
Thiamine Co-enzyme in Hemodynamic Consider monitoring and supplementation if on chronic, 
carbohydrate improvements in high-dose diuretic therapy; routine supplementation or 
metabolism patients receiving loop monitoring not recommended at this time except in 
diuretics cases of suspected alcoholic cardiomyopathy
Vitamin C Reduction in Increased myocardial Routine supplementation or monitoring not recommended
oxidative stress contractility with at this time
inotropes
Vitamin E Reduction in Increased incidence of Administration not recommended and may be harmful
oxidative stress HF in a cardiovascular
population
Coenzyme Q10 Mitochondrial Improved hemodynamic Administration may be reasonable but data is conflicting 
synthesis, reduction parameters, efficacy; lack of clear dose range (studied at 60-200 






Selenium Reduction in oxidative Reversal of Identify whether deficiency is present in new diagnosis of
stress cardiomyopathy in HF; routine supplementation or monitoring not
Keshan disease recommended at this time
Zinc Reduction in Unknown Routine supplementation or monitoring not recommended
oxidative stress at this time
Copper Reduction in Unknown Routine supplementation or monitoring not recommended
oxidative stress at this time
Fish Oil Unknown; may be Decreased mortality, Consider use (1 g/d) in all symptomatic HF patients
related to decrease cardiovascular 





Hawthorn Increased myocardial Improvements in Supplementation not recommended at this time
contractility, exercise capacity; 
improved endothelial reduced symptoms of 
function, reduction HF
in oxidative stress
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of HF and has been implicated in a number of studies and
case reports as a probable cause for cardiomyopathy.106-108
Excess parathyroid hormone levels have also been associ-
ated with increased blood pressure and contractility,109
which are potentially deleterious in a failing myocardium.
Loop diuretic therapy is also a well-known calciuric.110
Calcitriol (or 1,25-dihydroxyvitamin D3) administra-
tion has been associated with beneficial endocrine
response on the RAAS, reducing plasma renin activity,111
angiotensin II, and, subsequently, blood pressure.111,112
This may have important implications for a patient with
hypertension as an underlying etiology for HF. Schleithoff
et al reported the effects of vitamin D in addition to
calcium supplementation in a randomized, controlled
trial of 93 HF patients, demonstrating that those assigned
to the addition of 50 μg of vitamin D3 to 500 mg of
calcium had significantly decreased inflammatory markers
after 9 months.113
Low calcium levels are also associated with proar-
rhythmia,114 although typically only in cases of severe
deficit. If hypocalcemia is identified in a patient present-
ing with new onset HF as a possible etiology, it should be
treated aggressively with oral or IV calcium plus vitamin
D analogs to gradually normalize serum calcium levels.
Typically, calcium deficit in these cases is severe, with
total serum concentrations measuring as low as 3–7 mg/dL
or ionized calcium levels of <2 mg/dL. Case reports note
reversal of cardiomyopathy in several cases after pro-
longed supplementation.115,116 Given the potential adverse
effects of hypocalcemia and the high incidence of osteo-
porosis in the HF population,117 routine monitoring of
serum calcium is desirable in a patient on chronic loop
diuretic therapy and supplementation administered if
deficiency is identified. Further clinical trials should
explore the role of vitamin D as an anti-inflammatory
agent on disease progression in HF, but supplementation
should be considered if outdoor activity is limited by dis-
ability or climate, or if renal calcitriol synthesis is impaired
by poor renal perfusion (ie, cardiorenal syndrome) or
other comorbid conditions.
B vitamins. Riboflavin (vitamin B2) and pyridoxine (vitamin
B6) influence the production of red blood cells and play a
role in carbohydrate-mediated energy production. Similar to
thiamine, these vitamins are water soluble and have limited
tissue storage.105 Furthermore, a combination of B vitamins
(as part of a regimen of various micronutrients) has also
been shown to reduce blood pressure and improve vasodila-
tory response in an older adult population with HF.118
However, large-scale clinical evaluations are lacking in an
HF population. Supplementation of B vitamins, along with
folate, reduced serum homocysteine levels effectively119 but
failed to demonstrate reductions in cardiovascular morbid-
ity and mortality in large-scale clinical trials.120,121 B vitamin
deficiency may also be identified if macrocytic anemia is
present, which may contribute to or worsen symptoms in
patients with HF. Current evidence does not support the
monitoring or supplementation of B vitamins routinely,
except in cases in which macrocytic anemia is present or in
alcoholic cardiomyopathies.
Vitamin C. Vitamin C has been the subject of several inves-
tigations in both animals and humans with HF due to its
potent antioxidant effects. Mak and Newton demonstrated
that administration of vitamin C (2 g IV bolus followed by
50 mg/min infusion) augmented the inotropic response of
dobutamine in patients with normal left ventricular dys-
function, although not in those with decreased left ventric-
ular dysfunction.122 In addition, Shinke et al conducted a
trial in which 19 patients with ischemic HF after anterior
infarction were randomized to receive either vitamin C (2 g
IV bolus followed by 50 mg/min infusion) or placebo.123
Patients randomized to receive vitamin C exhibited an
increased inotropic response to 4 μg/kg/min of dobutamine.
Although these results are promising, future clinical trials
examining meaningful clinical end points should be con-
ducted before acute or chronic supplementation of vitamin
C is recommended.
Vitamin E. Vitamin E was once a promising supplement
for patients with coronary disease or those with high risk 
of developing coronary artery disease. Dietary intake of
vitamin E appeared to negatively correlate with the risk
of coronary artery disease. Like vitamin C, vitamin E
was thought to improve endothelial function, and initial
studies were promising in animal models. However, large-
scale clinical trials consistently failed to demonstrate a
benefit and even associated increased mortality from
routine vitamin E supplementation for prevention of
cardiovascular morbidity or mortality.124-126 In addition,
vitamin E supplementation in both the GISSI-Prevenzione
trial and the HOPE trial significantly increased the risk of
developing HF.126,127 This may be owing to paradoxical
pro-oxidative and myocardial depressive effects of vitamin
E.128 Vitamin E supplementation is not recommended in
patients with HF and may be harmful.
Coenzyme Q10. Coenzyme Q10 (CoQ10) is a vitamin-like
element that plays a large role in mitochondrial synthesis
and is a strong regulator of oxidative stress. Low plasma
levels of CoQ10 have been identified in patients with
HF.129 Multiple CoQ10 supplementation trials in HF
patients have been performed, with doses ranging from
60 mg/d to more than 200 mg/d.130-137 Unfortunately, the
results of these trials are largely conflicting. Many data,
although not all,131,133,134 show that CoQ10 improves
hemodynamic parameters in HF. Indeed, Sander et al
recently conducted a meta-analysis of 10 CoQ10 trials in
HF and found that the addition of CoQ10 vs placebo mod-
estly benefited several parameters of systolic function,
improving EF by a net of 3.7% (95% CI, 1.59-5.77;
P < .00001 for statistical heterogeneity).138 The effect was
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stronger in subgroups of patients not receiving an ACEI.
In addition, Morisco et al studied the addition of 2
mg/kg/d of CoQ10 to standard therapy, which was found to
reduce hospitalizations for HF compared with placebo
over 1-year follow-up (22.9% vs 36.6%, P < .001).132 CoQ10
deficiency is also a suspected cause of statin-induced
myopathy, statin drugs are widely prescribed medications
in the HF population.139,140 Investigations are ongoing as
to whether supplementation improves myopathy and tol-
erability. Given the conflicting data and the inconsistent
dosing surrounding the use of CoQ10 in HF, it is difficult
to make definitive recommendations regarding its use. In
addition, available HF guidelines do not endorse the use
of CoQ10 in HF. Nevertheless, its use may be reasonable,
particularly in a symptomatic patient unable to tolerate
standard of care medications. Large and well-designed
studies powered to assess optimal dosing, efficacy, and
safety of CoQ10 are required before widespread use is
recommended.
Other minerals. Selenium and zinc are 2 minerals that, like
many micronutrients, play a role in the regulation of oxida-
tive stress. Deficiencies of these minerals have been identi-
fied in patients with HF.141,142 Keshan disease, a
cardiomyopathy endemic to China, is primarily thought to
be caused by selenium deficiency.143 Case reports describe
reversible cardiomyopathies in patients receiving parenteral
nutrition as a result of selenium deficiency.144,145 The ACEIs
and ARBs are associated with zinc deficiency as previously
discussed,93,94 as are thiazide diuretics, which significantly
increase urinary zinc excretion.93 Loop diuretic use does not
appear to alter zinc concentration in humans.146
Other minerals have been identified as potential sup-
plementary therapy for HF patients. Similar to several
previously discussed supplements, copper and manganese
could affect the regulation of oxidative stress. Manganese
deficiency may play a role in the pathogenesis of doxoru-
bicin-induced cardiac toxicity.147 Copper deficiency is a
long-suspected cause of cardiomyopathy and other detri-
mental cardiovascular conditions.148 However, paradoxi-
cally elevated serum copper levels were shown in HF
patients when compared with copper levels of controls.149-
151 Definitive evidence regarding the etiology of increased
serum copper concentrations in the setting of other min-
eral deficiencies is lacking, although it is logical that cop-
per is a marker of oxidative stress. Elevation in serum
copper level also appears to be prognostic for morbidity
and mortality in HF patients.152
Although this evidence clearly advocates identifying
mineral deficiency in HF patients without a clear etiology,
fewer data examine the clinical effects of supplementation
in which the deficiency is not the identified cause of the
cardiomyopathy. Witte et al randomized 30 elderly HF
patients to a combination micronutrient regimen (contain-
ing calcium, magnesium, zinc, copper, selenium, vitamin
A, thiamine, riboflavin, vitamin B6, folate, vitamin B12,
vitamin C, vitamin E, vitamin D, and CoQ10) or placebo for
9 months in a double-blind, randomized controlled trial.118
At the end of the follow-up period, the micronutrient sup-
plementation group demonstrated modest although statisti-
cally significant gains in EF vs placebo and improved quality
of life. Although definitive clinical data are lacking regard-
ing mineral supplementation, it would be reasonable to
periodically monitor zinc levels in patients receiving ACEI/
ARB therapy or thiazide diuretics and supplement if defi-
ciency is identified. Selenium deficiency may be ruled out
as a reversible cause of cardiomyopathy, particularly those
endemic to areas with Keshan disease, but widespread mon-
itoring or supplementation has not been optimally evaluated
at this time. Patients receiving administered feedings, par-
ticularly parenteral nutrition, may require more intensive
monitoring. Supplemental administration of copper or man-
ganese has not been optimally evaluated at this time and is
not recommended.
Complementary and Alternative Medications
Complementary and alternative medications (CAMs) are
defined as therapies not commonly used in Western med-
icine and are treated as nutrition supplements by the
Food and Drug Administration (FDA) in the United
States. It is estimated that one-third of patients with HF
are taking CAMs.153 Researchers in the HERB-HF study
found that patients with HF took CAMs for treatment of
heart problems, anxiety, weight loss, and arthritis.153
Several of the CAMs taken by patients were noted to
interact with concomitant medications used in HF.
Fish oils, ω-3 polyunsaturated fatty acids, or ω-3 fatty
acids are commonly used in the treatment of elevated
serum triglyceride levels. Although the mechanism of
action is not completely understood, ω-3 fatty acids
appear to interfere with hepatic triglyceride synthesis,
producing favorable effects on serum levels of triglyc-
erides (–20% to –50%), very low density lipoprotein
(–20% to –40%), and high-density lipoproteins (5%-10%),
at the expense of unfavorable increases in low-density
lipoproteins (15%-30%).154,155 Beyond direct lipid effects,
other postulated actions of ω-3 fatty acids include favor-
able changes in arrhythmogenesis (decreased membrane
excitability), inflammation, platelet aggregation, blood
pressure, heart rate, ventricular function, and autonomic
tone. However, none of these actions has been systemat-
ically evaluated in HF patients.
A recent study examined the clinical efficacy of ω-3
fatty acids in HF patients without baseline lipid abnormali-
ties.156 Patients with NYHA class II to IV symptoms were
randomized to treatment with ω-3 fatty acids (Lovaza, 1 g
daily [n = 3494], GlaxoSmithKline, Research Triangle Park,
NC) or placebo (n = 3481). All study medications were in
addition to standard care regimens that consisted of
ACEIs/ARBs (77%/19%), beta-blockers (65%), and diuretics
Impact of Drug Therapy on Nutrition in Heart Failure / Dunn et al 69
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(90%). After a mean follow-up of 3.9 years, investigators
reported a small but statistically significant reduction in all-
cause mortality in patients receiving ω-3 fatty acids (27%)
vs placebo (29%; hazard ratio [HR], 0.91; 95% CI, 0.833–
0.998; P = .041). Among secondary outcomes, ω-3 fatty
acids reduced cardiovascular mortality (HR, 0.90; P = .045)
and cardiovascular admissions (HR, 0.93; P = .049) but did
not affect HF admissions, sudden cardiac death, patients
with myocardial infarction, or patients with stroke. There
were no significant increases in adverse events among
patients taking ω-3 fatty acids. Of note, this study used an
FDA-approved formulation of prescription ω-3 fatty acids
indicated for the treatment of very-high serum triglyceride
levels (>500 mg/dL).
Ma huang is a nutrition supplement that many
patients use for weight loss, either alone or in combina-
tion with other CAMs. Ma huang is also commonly used
in the treatment of asthma, obesity, colds, fever, and
chills.157 It has been suggested that ma huang contains
1% ephedrine and therefore contributes to weight loss
through SNS stimulation. Stimulation of the SNS has led
to serious complications with ma huang use. Two recent
reviews reported that ma huang was temporally related to
cases of stroke, HF, myocardial infarction, and sudden
death.158,159 Furthermore, cardiovascular toxic effects
were not necessarily related to excessive doses of ma
huang.160 Based on these reported risks, patients with HF
should not use ma huang. In April 2004, the FDA
announced a ban on ephedrine-containing dietary prod-
ucts because of the risk of harm to the public.161
Hawthorn is the most well-studied CAM for the treat-
ment of HF. The pharmacological effects of hawthorn come
from the flavonoids found in the leaf, fruit, or flower of
these plants.162 The beneficial effects of flavonoids in HF
include increases in the force of contraction, improved
coronary blood flow, and higher cardiac output. After 16
weeks of hawthorn therapy combined with diuretics,
improvements in exercise capacity and reduced symptoms
of HF were observed.163 The difficulty in recommending
hawthorn as a standard therapy in patients with HF is that
such use has not been rigorously studied in large random-
ized clinical trials in patients on standard medical therapy.
To date, neither the ACC/AHA nor the Heart Failure
Society of America guidelines advocate the use of hawthorn
in patients with HF.
In a recent survey, 82% of patients with HF reported
use of an over-the-counter medication at least once per
week, which included nonsteroidal anti-inflammatory
drugs (NSAIDs).164 These NSAIDs, such as ibuprofen,
ketoprofen, and naproxen, inhibit the breakdown of
arachidonic acid via the cyclooxygenase enzyme and are
used for the treatment of pain and inflammation.
Cyclooxygenase enzyme inhibition also interrupts renal
blood flow, causing fluid retention. This effect is particu-
larly detrimental in patients with HF because fluid reten-
tion produced by NSAIDs may counteract the fluid
restriction and medications used to control intravascular
and extravascular volume. One study reported a 2-fold
increase in HF admission among patients with HF taking
NSAIDs compared with admission rate of those not taking
NSAIDs.165 Patients with HF should be encouraged to use
acetaminophen in place of NSAIDs for pain and headache.
Conclusion
Research regarding nutrition aspects of HF is limited. 
In fact, the National Institutes of Health recently
announced a funding program specifically targeting nutri-
tion and HF (PA-06-136, Nutrition and Diet in the
Causation, Prevention, and Management of Heart
Failure, R21). Despite this encouraging news, we as prac-
titioners have very little guidance or evidence-based
approaches addressing dietary issues, including supple-
ments, for our HF patients. Fortunately, concepts can be
put forth that are reasonable, embroil little controversy,
and will likely be of benefit for the patient. An initial step
to consider for patients is to evaluate current nutrition
status and dietary pattern and, if needed, consult the
patient regarding healthy dietary choices (which may
include sodium restriction). For many patients, an
appointment with a nutrition expert may be beneficial,
especially if a patient appears to be malnourished.
Working with a registered dietitian may lead to healthier
dietary choices, which may reduce overall cardiac risk. In
addition, counseling patients about foods that may have
high amounts of potassium may be appropriate for
individual patients taking certain drugs or combination
of drugs. Obviously, patients at risk for electrolyte
disturbances due to drug therapy (ie, hyperkalemia,
hypokalemia, or hypomagnesemia) must be routinely
monitored and supplemented as necessary. For patients
who appear to be cachectic, the best approach to revers-
ing cachexia is not known but must include at least opti-
mization of standard of care medications for HF. Addition
of secondary drugs such as aldosterone antagonists or
angiotensin II blockers should be considered if a patient
has continued symptoms of HF. Another consideration
for patients with documented calcium deficiency is to
recommend calcium supplementation. Beyond these gen-
eral recommendations, how we should nutritionally treat
HF patients is not known and is left to clinical judgment.
For example, although it appears reasonable that patients
taking diuretics or patients who live in northern climates
should be routinely given a vitamin supplement that
includes thiamine, vitamin D, CoQ10, and perhaps vita-
min C, we have no outcome data. Without outcome data,
it is not advisable to make this a general recommendation
(see vitamin E). However, when evaluating an individual
patient, clinical circumstances and judgment may suggest
that vitamin supplementation is reasonable. Overall, this
example highlights the fact that the role of nutrition in
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the development and progression of HF has been an
area that until recently has been largely ignored. Fortunately,
this is changing, and it is hoped that in addition to drug
therapy, nutrition aspects to the management of HF will
be at the forefront of care.
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